ADVERTISEMENT
Search

 

Press Releases

 

16

May

2024

Coming off GLP-1s slowly could be key to preventing weight regain

Author: Anonym

Despite concerns about patients regaining weight after stopping GLP-1 receptor agonists like semaglutide and tirzepatide, new research suggests that such gains aren’t necessarily the case. The key, the findings suggest, lies in gradually weaning off the drug instead of withdrawing abruptly and completely, and then continuing to make healthy choices.

Comments (0)
Number of views (35047)
Article rating: 4.3
Read more

Categories: APhA News

Tags: APhA News

10

May

2024

For smoking cessation, increasing dose may help improve abstinence

Author: Anonym

Most people who smoke don’t quit on their initial attempt. What’s the best course of action, then, if an initial smoking cessation attempt fails? Results from a randomized clinical trial published in JAMA Network found that for individuals who did not quit after being treated with varenicline, increasing the dosage enhanced abstinence. For nonabstainers who were initially treated with combination nicotine replacement therapy, a dosage increase or a switch to varenicline enhanced abstinence.

Comments (0)
Number of views (2330)
Article rating: No rating
Read more

Categories: APhA News

Tags: APhA News

10

May

2024

Under new law, pharmacist scope of practice expands in Tennessee

Author: Anonym

Governor Bill Lee of Tennessee signed legislation that expands pharmacists’ scope of practice in the state. The law took effect immediately upon the governor’s signature on May 1.

Comments (0)
Number of views (6542)
Article rating: 5.0
Read more

Categories: APhA News

Tags: APhA News

6

May

2024

AHA wants to engage pharmacists in AFib care

Author: Anonym

A new initiative from the American Heart Association (AHA) aims to educate and engage pharmacists in caring for patients with AFib.

Comments (0)
Number of views (2570)
Article rating: 5.0
Read more

Categories: APhA News

Tags: APhA News

3

May

2024

Migraine associated with PPIs and other acid suppressing medications, says study

Author: Anonym

A study of more than 11,000 U.S. adults suggests an association between acid-suppression therapy, including PPIs, H2RAs, and generic antacids, and an increased risk of migraine and severe headaches compared with people who do not take these medications. The risk was 70% higher for those using PPIs, 40% higher for those taking H2RAs, and 30% higher for generic antacids.

Comments (0)
Number of views (2710)
Article rating: No rating
Read more

Categories: APhA News

Tags: APhA News

RSS
123468910Last
Advertisement
Advertisement
Advertisement
Advertisement
ADVERTISEMENT